Strategic Partnerships Gandeeva has a history of high-profile collaborations with Moderna and Zymeworks, indicating openness to externally funded programs and co-development initiatives that can be expanded to target oncology, protein interactions, or antibody-antigen interface projects.

Cryo-EM & ML Advantage The company pairs cryo-EM with machine learning for structure-guided drug discovery, offering a unique value proposition for partnerships aiming to accelerate lead optimization and reduce discovery timelines, particularly in difficult-to-target oncology programs.

Preclinical Oncology Focus With a robust preclinical oncology pipeline and novel modalities like iGlues and allosteric inhibitors, Gandeeva presents opportunities for CRO, biotech, and pharma collaborations seeking early-stage asset discovery, validation, and fast-to-clinic pathways.

Funding & Growth Having raised $40M in Series A and maintaining a lean team, Gandeeva may be seeking strategic alliances or grant-backed programs to scale capabilities, expand platform reach, and co-sponsor research efforts.

Integrated Platform The SPOTLIGHT, HYPERFOCUS, and CRYO-CADD platforms offer end-to-end discovery capabilities, presenting cross-selling potential for partners needing target prediction, hit discovery, and lead optimization under a single, integrated workflow.